Post-discharge Malaria Chemoprevention(PMC) Study (PMC)
Malaria Chemoprevention With Monthly Treatment With Dihydroartemisinin-piperaquine for the Post-discharge Management of Severe Anaemia in Children Aged Less Than 5 Years in Uganda and Kenya: A Two-arm Randomised Placebo Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Kisumu, Kenya
- Jaramogi Oginga Odinga Teaching and Referral Hospital
-
-
Homa Bay County
-
Homa Bay, Homa Bay County, Kenya, 40100
- Homa Bay County Referral Hospital
-
-
Migori County
-
Migori, Migori County, Kenya, 40400
- Migori County Referral Hospital
-
-
Siaya County
-
Siaya, Siaya County, Kenya, 40100
- Siaya County Referral Hospital
-
-
-
-
-
Hoima, Uganda
- Hoima Regional Referral Hospital
-
Jinja, Uganda
- Jinja Regional Referral Hospital
-
Kamuli, Uganda
- Kamuli Mission Hospital
-
Masaka, Uganda
- Masaka Regional Referral Hospital
-
Mubende, Uganda
- Mubende Regional Referral Hospital:
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Pre-study screening
- Haemoglobin <5.0 g/dl or PCV < 15%, or requirement for blood transfusion for other clinical reasons on or during admission to the hospital
- Aged less than 59.5 months
- Body weight >5 kg
- Resident in catchment area Enrolment in study(t=0)
- Fulfilled the pre-study screening eligibility criteria
- Aged < 59.5 months
- Clinically stable, able to take oral medication
- Subject completed blood transfusion(s) or became clinically stable without transfusion
- Able to feed (for breastfeeding children) or eat (for older children)
- Absence of know cardiac problems
- Provision of informed consent by parent or guardian Randomisation (t=2 weeks)
- Fulfilled enrolment eligibility criteria and was enrolled during recent admission
- Aged <60 months
- Still clinically stable, able to take to oral medication, able to feed (for breastfeeding children) or eat (for older children) and able to sit unaided (for older children who were already able to do so prior to hospitalisation)
Exclusion Criteria:
Pre-study screening
- Recognised specific other cause of severe anaemia (e.g. trauma, haematological malignancy, known bleeding disorder)
- Known sickle cell disease
- Anticipated to reach the 5th birthday (60 months of age) within 2 weeks from enrolment (i.e. prior to randomization)
- Child will reside for more than 25%of the 6 months study period (i.e. 6 weeks or more) outside of catchment area Enrolment in study (t=0)
- Previous enrolment in the present study
- Known hypersensitivity to study drug
- Sickle cell disease
- Use or known need at the time of enrolment for concomitant prohibited medication during the 14 weeks PMC treatment period.
- Ongoing or planned participation in another clinical trial involving ongoing or scheduled treatment with prohibited medicinal products or active follow-up during the course of the study (6 months from enrolment)
- A known need at the time of enrolment for scheduled surgery during the subsequent course of the study (6 months from enrolment)
- Suspected non-compliance with the follow-up schedule
- Know heart conditions, or family history of congenital prolongation of the QTc interval.
- Taking medicinal products that are known to prolong the QTc interval Randomisation (t=2 weeks)
- Used dihydroartemisinin since enrolment
- Use or known need at the time of randomisation for concomitant prohibited medication during the 14 weeks PMC treatment period.
- Enrolled, or known agreement to enrol into another clinical trial involving ongoing or scheduled treatment with medicinal products during the course of the study (6 months from enrolment)
- A known need at the time of randomisation for scheduled surgery during the subsequent course of the study (6 months from enrolment)
- Suspected non-compliance with the follow-up schedule
- Withdrawal of consent since enrolment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: dihydroartemisinin-piperaquine
dihydroartemisinin-piperaquine (3-day treatment courses, given 2, 6, and 10 weeks after enrollment)
|
Children in both arms will receive standard in-hospital care for severe anaemia (blood transfusion, often combined with quinine or artesunate IV/IM).
All children will then receive a 3-day course of AL (whether they initially had malaria or not), which will be started in-hospital as soon as they are able to take oral medication, and will be completed at home after discharge.
At 2 weeks after enrolment surviving children will be randomized to receive either a standard 3-day courses of dihydroartemisinin-piperaquine (Eurartesim®, Sigma Tau, Italy) or an identical placebo regimen at 2, 6 and 10 weeks after enrolment.
Other Names:
|
|
PLACEBO_COMPARATOR: dihydroartemisinin-piperaquine Placebo
Placebo comparator (matching tablets containing no active ingredients)
|
Children will receive standard in-hospital care for severe anaemia (blood transfusion, often combined with quinine or artesunate IV/IM).
All children will then receive a 3-day course of AL (whether they initially had malaria or not), which will be started in-hospital as soon as they are able to take oral medication, and will be completed at home after discharge.
At 2 weeks after enrolment surviving children will be randomized to receive either a standard 3-day courses of dihydroartemisinin-piperaquine (Eurartesim®, Sigma Tau, Italy) or an identical placebo regimen at 2, 6 and 10 weeks after enrolment.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
All-cause deaths or all-cause re-admissions by 26 weeks from randomization (composite primary outcome).
Time Frame: 6 months
|
Primary outcome
|
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Readmission due to severe malaria (defined as any treatment with parenteral quinine or artesunate, or presence of severe anaemia and treatment with oral antimalarials) by 26 weeks from randomization
Time Frame: 26 weeks from randomization
|
26 weeks from randomization
|
|
All-cause readmission by 26 weeks from randomization
Time Frame: 26 weeks from randomization
|
26 weeks from randomization
|
|
Readmissions due to severe anaemia (defined as Haemoglobin (Hb) <5g/dL or packed-cell volume (PCV) <15% or requirement for blood transfusion based on other clinical indication)by 26 weeks from randomization
Time Frame: 26 weeks from randomization
|
26 weeks from randomization
|
|
Readmission due to severe malarial anaemia (severe anaemia plus parenteral or oral antimalarial treatment)by 26 weeks from randomization
Time Frame: 26 from randomization
|
26 from randomization
|
|
Readmission due to severe anaemia or severe malaria (composite outcome)by 26 weeks from randomization
Time Frame: 26 weeks from randomization
|
26 weeks from randomization
|
|
All-cause mortality by 26 weeks from randomization
Time Frame: 26 weeks from randomization
|
26 weeks from randomization
|
|
Clinic visits because of smear of rapid diagnostic test (RDT) confirmed non-severe malaria by 26 weeks from randomization
Time Frame: 26 weeks from randomization
|
26 weeks from randomization
|
|
Readmission due to severe malaria-specific anaemia (severe anaemia plus parenteral or oral antimalarial treatment and parasite density >5000/microlitre) by 26 weeks from randomization
Time Frame: 26 weeks from randomization
|
26 weeks from randomization
|
|
Readmission due to severe disease other than severe anaemia and severe malaria by 26 weeks from randomization
Time Frame: 26 weeks from randomization
|
26 weeks from randomization
|
|
Non-severe all-cause sick-child clinic visits by 26 weeks from randomization
Time Frame: 26 weeks from randomization
|
26 weeks from randomization
|
|
Non-malaria sick child clinic visits by 26 weeks from randomization
Time Frame: 26 weeks from randomization
|
26 weeks from randomization
|
|
Malaria infection at 6 month
Time Frame: 6 month
|
6 month
|
|
Hb at 6 months
Time Frame: 6 months
|
6 months
|
|
Any anaemia (Hb<11 g/dL), mild anaemia (Hb 8.0-10.99 g/dl) moderate anaemia (Hb 5.0-7.99 g/dL) and severe anaemia (Hb<5 g/dL) at 6 months
Time Frame: 6 months
|
6 months
|
|
Weight-for-age, height-for-age, and height-for-weight Z-scores, standard deviation (SD) scores of reference population) at 6 months
Time Frame: 6 months
|
6 months
|
|
Serious adverse events, excluding primary and secondary efficacy outcomes, by 26 weeks from randomization
Time Frame: 26 weeks from randomization
|
26 weeks from randomization
|
|
Serious adverse events within 7 days after the start of each course of PMC, excluding primary and secondary efficacy outcomes.
Time Frame: 26 weeks from randomization
|
26 weeks from randomization
|
|
Adverse events by 26 weeks from randomization
Time Frame: 26 weeks from randomization
|
26 weeks from randomization
|
|
Adverse events within 7 days after start of each course of PMC.
Time Frame: 7 days post drug administration
|
7 days post drug administration
|
|
Corrected QT interval (QTc) prolongation measured by electro cardio gram (ECG)4-6 hours after 3rd dose of each course
Time Frame: 4-6 hours after 3rd dose of each course
|
4-6 hours after 3rd dose of each course
|
|
Patients costs of receiving the intervention
Time Frame: 26 weeks after randomization
|
26 weeks after randomization
|
|
Patients costs related to treatment of the primary disease, readmission or death
Time Frame: 26 weeks after randomization
|
26 weeks after randomization
|
|
The costs of the health care system of providing the intervention
Time Frame: 26 weeks after randomization
|
26 weeks after randomization
|
|
The costs of the health system of treating the primary disease and anaemia, as well as treatment of readmissions or costs related to fatalities
Time Frame: 26 weeks after randomization
|
26 weeks after randomization
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Dr Titus K Kwambai, MSc, Liverpool School of Tropical Medicine
- Principal Investigator: Dr Simon K Kariuki, PhD, Kenya Medical Research Institute
- Principal Investigator: Dr Richard IDRO, PhD, Makerere University
- Principal Investigator: Dr Robert Opoka, M.Med, Makerere University
Publications and helpful links
General Publications
- Kwambai TK, Dhabangi A, Idro R, Opoka R, Watson V, Kariuki S, Kuya NA, Onyango ED, Otieno K, Samuels AM, Desai MR, Boele van Hensbroek M, Wang D, John CC, Robberstad B, Phiri KS, Ter Kuile FO. Malaria Chemoprevention in the Postdischarge Management of Severe Anemia. N Engl J Med. 2020 Dec 3;383(23):2242-2254. doi: 10.1056/NEJMoa2002820.
- Kwambai TK, Dhabangi A, Idro R, Opoka R, Kariuki S, Samuels AM, Desai M, van Hensbroek MB, John CC, Robberstad B, Wang D, Phiri K, Ter Kuile FO. Malaria chemoprevention with monthly dihydroartemisinin-piperaquine for the post-discharge management of severe anaemia in children aged less than 5 years in Uganda and Kenya: study protocol for a multi-centre, two-arm, randomised, placebo-controlled, superiority trial. Trials. 2018 Nov 6;19(1):610. doi: 10.1186/s13063-018-2972-1.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 14.034
- 2965 (OTHER: Kenya Medical Research Institute)
- 2015-125 (OTHER: Uganda REC)
- 2014/1911 (OTHER: Norway REC)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.